Enliven Therapeutics increased its research and development spending in the fourth quarter of fiscal 2024 as several drug ...

Shares of Altimmune (NASDAQ:ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors on ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.

Effective drug discovery and development hinge on high-quality data. Implementing FAIR principles enhances data usability and ...

Entos Pharmaceuticals has announced an investment of C$62m ($43.05m) from the governments of Canada and Alberta for an R&D facility.

Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop ...

Under the terms of the agreement, RedRidge will provide its capabilities to engineer, screen and characterize BPAs against an undisclosed portfolio of jointly nominated targets, while Pierre Fabre ...

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...